← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

Alpha 1 Antitrypsin Deficiency

MONDO:0013282 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 31 citations openscientist · 48 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

Alpha-1 antitrypsin deficiency is caused by pathogenic SERPINA1 variants, most importantly the Z allele (a glutamic acid to lysine substitution at residue 342), which destabilizes the AAT molecule and promotes its misfolding and polymerization.

UNANIMOUS INTEGRATED
genetic_factorpathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 92% described as a glutamic acid→lysine substitution (position 342) that produces a misfolded protein prone to polymerization and hepatocyte retention, with severe deficiency
Falcon names the Z variant as the Glu-to-Lys position-342 substitution and ties it directly to misfolding, polymerization, and hepatocyte retention.
openscientist CONCORDANT 95% The Glu342Lys substitution destabilizes the relationship between the reactive center loop (RCL) and beta-sheet A, creating a kinetically trapped intermediate prone to intermolecular domain swapping
OpenScientist gives the same Glu342Lys lesion and adds the structural mechanism (RCL/beta-sheet A destabilization and domain swapping).

AATD injures target organs through two simultaneous mechanisms: a loss-of-function arm (reduced circulating AAT) driving lung disease and a gain-of-toxic-function arm (intracellular Z-AAT polymer retention) driving liver disease.

UNANIMOUS INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 90% reduce circulating AAT levels and/or produce dysfunctional AAT (loss of antiprotease function), and (for Z-type variants) promote misfolding/polymerization with hepatocellular retention (gain-of-toxic-function in liver)
Falcon distinguishes the lung loss-of-antiprotease-function arm from the hepatic gain-of-toxic-function arm.
openscientist CONCORDANT 95% The AAT deficiency is unique among the protein-misfolding diseases in that it causes target organ injury by both loss-of-function and gain-of-toxic function mechanisms
OpenScientist quotes Kalsheker et al. asserting the dual loss-of-function / gain-of-toxic-function mechanism as unique among misfolding diseases.

Reduced functional AAT removes inhibition of neutrophil elastase, producing a protease-antiprotease imbalance in which unopposed elastase degrades lung elastin and drives progressive emphysema.

UNANIMOUS INTEGRATED
pathophysiologygene_function
ProviderStanceScoreEvidence
falcon CONCORDANT 90% reduced circulating functional AAT removes inhibition of neutrophil elastase (NE) and related proteases (loss of antiprotease protection)
Falcon states loss of AAT removes neutrophil elastase inhibition, the core of the protease-antiprotease imbalance.
openscientist CONCORDANT 92% loss of effective antiprotease protection results in unchecked neutrophil elastase activity and progressive lung tissue destruction
OpenScientist gives the same protease-antiprotease-imbalance chain from lost antiprotease protection to lung destruction.

The predominant pulmonary manifestation is early-onset emphysema, classically presenting before age 50 with a panacinar, lower-lobe-predominant pattern.

UNANIMOUS INTEGRATED
phenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 80% classically earlier-onset emphysema (often before age 50) with heterogeneity in lobar patterns; protease–antiprotease imbalance drives progressive tissue destruction
Falcon reports early-onset emphysema (often before 50) as the core pulmonary phenotype but frames lobar pattern as heterogeneous.
openscientist CONCORDANT 85% The most common genotype associated with pulmonary disease is the ZZ genotype, and the most frequent pulmonary manifestation is emphysema
OpenScientist agrees emphysema is the most frequent pulmonary manifestation and elsewhere specifies basal/panacinar distribution.

Severe (Pi*ZZ) AATD affects roughly 1 in 2,000–3,500 individuals of Northern European descent, making it one of the more common Mendelian disorders in that population.

MAJORITY INTEGRATED
epidemiology
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% AATD affects approximately 1 in 2,000–3,500 individuals of Northern European descent
OpenScientist gives the 1 in 2,000–3,500 Northern European prevalence figure directly.
falcon PARTIAL 70% ~1:2,000–5,000 in Europe; ~1:5,000–7,000 in countries with substantial European immigration
Falcon reports an overlapping but wider Pi*ZZ prevalence range (1:2,000–5,000 in Europe), so it is partially concordant on the rate.

AATD is severely underdiagnosed, with only about 10% of affected individuals identified.

UNANIMOUS INTEGRATED
epidemiologydiagnosis
ProviderStanceScoreEvidence
falcon CONCORDANT 90% Unfortunately, underdiagnosis is quite common; it is possible that only 10% of cases are diagnosed
Falcon quotes the Feitosa guideline that only ~10% of cases are diagnosed.
openscientist CONCORDANT 90% an estimated 90% of affected individuals are never identified
OpenScientist states ~90% are never identified, the complement of the same underdiagnosis claim.

Intravenous augmentation therapy with plasma-derived AAT (standard 60 mg/kg weekly) is the only disease-specific therapy for AATD emphysema and slows CT densitometry-measured lung-density decline.

UNANIMOUS INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 90% weekly IV 60 mg/kg is the standard regimen; alternative regimens have been explored but may provide less consistent time above protective thresholds
Falcon gives the standard 60 mg/kg weekly regimen and frames augmentation as the only specific disease-modifying therapy.
openscientist CONCORDANT 92% The RAPID trial demonstrated slowed progression of emphysema measured by CT density decline: 0.79 g/L/year treatment difference vs. placebo
OpenScientist reports the RAPID trial CT-density benefit and also calls augmentation the only disease-specific approved lung therapy.

Liver-targeted RNA interference against hepatic SERPINA1 is an emerging strategy that can substantially knock down Z-AAT (about 78% reduction in first-in-human data), addressing the gain-of-function arm not treated by augmentation.

MAJORITY LEAD
treatment
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% RNA interference (achieving ~78% Z-AAT knockdown)
OpenScientist quantifies the ~78% Z-AAT knockdown from the ARC-AAT first-in-human RNAi study.
falcon PARTIAL 50% Phase 1/2 RNAi therapeutic trial in ZZ liver disease was terminated due to transient liver enzyme elevations
Falcon lists an earlier liver-targeted RNAi program (ALN-AAT) but only as a terminated trial, without the knockdown magnitude — partial agreement on the modality, silent on the efficacy figure.

Liver transplantation is curative for the hepatic component of AATD (the graft produces normal M-AAT) and achieves excellent long-term survival (~89% at 20 years).

SINGLE INTEGRATED
treatmentprognosis
ProviderStanceScoreEvidence
openscientist CONCORDANT 92% Curative for liver disease; corrects the metabolic defect (donor liver produces normal M-AAT); excellent 20-year survival of 89%
OpenScientist reports liver transplant as curative with 89% 20-year survival.
falcon SILENT —
Falcon's treatment section covers augmentation and investigational agents but does not address liver transplantation or its outcomes.

Narrative

Overview

Both providers frame Alpha-1 antitrypsin deficiency as an autosomal codominant SERPINA1 disorder in which the Z allele (Glu342Lys) misfolds and polymerizes, producing a dual pathology: loss of circulating antiprotease protection driving early-onset emphysema, and hepatocellular retention of Z-AAT polymers driving liver fibrosis, cirrhosis, and hepatocellular carcinoma. Falcon is a concise guideline/registry-anchored report; the OpenScientist report is broader and more quantitative, with mechanistic, epidemiologic, and therapeutic detail.

Agreement

The reports converge on the core biology: the SERPINA1 Z variant as the dominant lesion, the protein misfolding/polymerization/ER-retention chain, the dual loss-of-function (lung) and gain-of-toxic-function (liver) mechanism, the protease-antiprotease imbalance with unopposed neutrophil elastase, early-onset emphysema as the predominant pulmonary phenotype, marked underdiagnosis (~10% diagnosed), and IV augmentation therapy (60 mg/kg weekly) as the only disease-specific lung treatment.

Divergence

Divergence is mostly coverage and quantitative precision rather than contradiction. OpenScientist adds figures Falcon lacks — the RAPID CT-density benefit, ~78% RNAi knockdown, liver-transplant 20-year survival (89%), mortality rate ratio 6.2, and the polymer-load/fibrosis-outcome correlation — and reports a narrower Pi*ZZ prevalence (1:2,000–3,500) versus Falcon's wider 1:2,000–5,000. Falcon uniquely catalogues the recent investigational trial landscape (INBRX-101/SAR447537, KB408 inhaled HSV-1 SERPINA1 delivery, NTLA-3001 CRISPR, ALN-AAT) and the EARCO registry, and it is silent on liver transplantation.

Integration

The concordant driver biology (Z-allele misfolding, dual mechanism, protease-antiprotease imbalance), the emphysema phenotype, prevalence and underdiagnosis, and augmentation therapy are promoted as curated content. Liver transplantation with long-term survival is integrated on the OpenScientist evidence.

Not integrated (leads)

Emerging liver-directed RNAi is retained as a research lead pending verification of the knockdown figures and trial provenance; the broader investigational pipeline (recombinant/inhaled A1PI, gene editing), drug-repurposing signals, and single-registry epidemiologic point estimates are kept as leads rather than promoted.

Cross-provider synthesis comparing the falcon and openscientist deep-research reports for Alpha-1 antitrypsin deficiency. No direct contradictions were found; divergence is coverage and quantitative precision (prevalence range, therapeutic efficacy figures, and OpenScientist-only liver-transplant and polymer-load data that Falcon omits). Note the two reports also disagree on the MONDO mapping (falcon: MONDO:0013282, openscientist: MONDO:0011073); the header uses MONDO:0013282 per kb/disorders/Alpha_1_Antitrypsin_Deficiency.yaml. best_matching_text values are verbatim excerpts from the cited report files; literature evidence snippets were intentionally left unpopulated pending fetch-reference verification of the underlying PMIDs/DOIs.